310430-94-5

Basic information

• Product Name: Pyrrolo[2,1-f][1,2,4]triazin-4(1H)-one, 7-methyl- (9CI)
• Synonyms: Pyrrolo[2,1-f][1,2,4]triazin-4(1H)-one, 7-methyl- (9CI)
• CAS NO: 310430-94-5
• Molecular Formula: C₇H₇N₃O
• Molecular Weight: 149.152
• Product Categories: ALCOHOL
• Mol File: 310430-94-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Pyrrolo[2,1-f][1,2,4]triazin-4(1H)-one, 7-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrrolo[2,1-f][1,2,4]triazin-4(1H)-one, 7-methyl- (9CI)(310430-94-5)
• EPA Substance Registry System: Pyrrolo[2,1-f][1,2,4]triazin-4(1H)-one, 7-methyl- (9CI)(310430-94-5)

Safety Data

• Hazardous Substances Data: 310430-94-5(Hazardous Substances Data)

Upstream product

• 310430-93-4 1-amino-5-methyl-1H-pyrrole-2-carboxamide 
• 310430-92-3 1-amino-5-methyl-1H-pyrrole-2-carbonitrile 
• 1192-79-6 formyl-2 methyl-5 pyrrole 
• 636-41-9 2-methyl-1H-pyrrole 
• 64-18-6 formic acid 

Relevant articles and documents

PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS

The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R5, R5′, R6, X1, X2, m, and n are described herein.

TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF

The present invention discloses triazine compounds of Formula II and a process to synthesize these compounds. Particularly, the invention provides one pot method to synthesize triazines nucleus, wherein the method comprises amination followed by using Leuckart reaction conditions of pyrrole/indole-2-carboxylates of Formula I to obtain corresponding triazine compounds of Formula II.

Pyrrolotriazine inhibitors of kinases

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template

The pyrrolo[2,1-f][1,2,4]triazine nucleus was identified as a novel kinase inhibitor template which effectively mimics the well-known quinazoline kinase inhibitor scaffold. Attachment of a 4-((3-chloro-4-fluorophenyl)amino) substituent to the template provided potent biochemical inhibitors of the tyrosine kinase activity of EGFR, as well as inhibition of cellular proliferation of the human colon tumor cell line DiFi. Attachment of a 4-((3-hydroxy-4-methylphenyl)amino) substituent provided potent inhibitors of VEGFR-2 which also showed effects on the VEGF-dependent proliferation of human umbilical vein endothelial cells. Biological activity was maintained with substitution at positions 5 or 6, but not 7, suggesting that the former positions are promising sites for introducing side chains which modulate physicochemical. properties. Preliminary inhibition studies with varying ATP concentrations suggest that, like the quinazoline-based kinase inhibitors, the pyrrolotriazine-based inhibitors bind in the ATP pocket.